The risk of deep venous thrombosis and pulmonary embolism in giant cell arteritis: a general population-based study

Aviña‐Zubieta, J Antonio; Bhole, Vidula; Amiri, Nasrin; Sayre, Eric C.; Choi, Hyon K.

doi:10.1136/annrheumdis-2014-205665

Cited by 70 publications

(68 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The finding of higher rates of venous thrombo-embolic diseases (VTEs) among patients with GCA compared with the reference population is consistent with prior studies demonstrating increased rates of hypercoagulability among patients with GCA and other forms of vasculitis (25)(26)(27)(28). The reason for the association between GCA and high rate of VTEs is not clear.…”

Section: Discussionsupporting

confidence: 74%

Rate of Comorbidities in Giant Cell Arteritis: A Population-based Study

et al. 2016

View full text Add to dashboard Cite

Objective.To compare the rate of occurrence of comorbidities, including severe infections, in a population-based cohort of patients with biopsy-proven giant cell arteritis (GCA) with a reference population in Southern Sweden.Methods.The study included a population-based cohort of biopsy-proven GCA cases diagnosed between 1998 and 2010 from the Skåne region in Southern Sweden (population: 1.2 million). For each patient, 4 reference subjects were identified from the general population and matched for age, sex, area of residence, and date of diagnosis of GCA. Using the Skåne Healthcare Register, comorbidities and severe infections (requiring hospitalization) diagnosed after GCA onset were identified. The rate of the first occurrence of each comorbidity was the result of dividing the number of subjects with a given comorbidity by the person-years of followup. The rate ratio (RR; GCA:reference population) was also calculated.Results.There were 768 patients (571 women) with GCA and 3066 reference persons included in the study. The RR were significantly elevated for osteoporosis (2.81, 95% CI 2.33–3.37), followed by venous thromboembolic diseases (2.36, 95% CI 1.61–3.40), severe infections (1.85, 95% CI 1.57–2.18), thyroid diseases (1.55, 95% CI 1.25–1.91), cerebrovascular accidents (1.40, 95% CI 1.12–1.74), and diabetes mellitus (1.29, 95% CI 1.05–1.56). The RR for ischemic heart disease was elevated, but did not reach statistical significance (1.20, 95% CI 1.00–1.44).Conclusion.Patients with GCA have higher rates of selected comorbidities, including severe infections, compared with a reference population. Several of these comorbidities may be related to treatment with glucocorticosteroids, emphasizing the unmet need to find alternative treatments for GCA.

show abstract

Section: Discussionsupporting

confidence: 74%

Rate of Comorbidities in Giant Cell Arteritis: A Population-based Study

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Avina-Zubieta et al reported increased risk of VTE in patients with GCA at the 2012 American College of Rheumatology annual meeting. 50 The health data of all residents in British Columbia, Canada from 1990-2007 were examined. The incidence rate of PE was 5.2 per 1000 person-years and that of VTE was 5.8 per 1000 person-years.…”

Section: Primary Systemic Vasculitidesmentioning

confidence: 99%

Venous thromboembolism in systemic autoimmune diseases: A narrative review with emphasis on primary systemic vasculitides

Tamaki

Khasnis

2015

Vasc Med

View full text Add to dashboard Cite

Venous thromboembolism (VTE) is a prevalent multifactorial health condition associated with significant morbidity and mortality. Population-based epidemiological studies have revealed an association between systemic autoimmune diseases and deep venous thrombosis (DVT)/VTE. The etiopathogenesis of increased risk of VTE in systemic autoimmune diseases is not entirely clear but multiple contributors have been explored, especially in the context of systemic inflammation and disordered thrombogenesis. Epidemiologic data on increased risk of VTE in patients with primary systemic vasculitides (PSV) have accumulated in recent years and some of these studies suggest the increased risk while patients have active diseases. This could lead us to hypothesize that venous vascular inflammation has a role to play in this phenomenon, but this is unproven. The role of immunosuppressive agents in modulating the risk of VTE in patients with PSV is not yet clear except for Behçet's disease, where most of the studies are retrospective. Sensitizing physicians to this complication has implications for prevention and optimal management of patients with these complex diseases. This review will focus on the epidemiology and available evidence regarding pathogenesis, and will attempt to summarize the best available data regarding evaluation and treatment of these patients.

show abstract

“…2 We agree that all systemic autoimmune rheumatic diseases (SARDs) are associated with an increased risk of VTE, as we and others have reported.…”

mentioning

confidence: 50%

Response to: ‘Venous thromboembolic events in systemic vasculitis’ by Novikovet al

et al. 2014

Self Cite

View full text Add to dashboard Cite

The risk of deep venous thrombosis and pulmonary embolism in giant cell arteritis: a general population-based study

Cited by 70 publications

References 43 publications

Rate of Comorbidities in Giant Cell Arteritis: A Population-based Study

Rate of Comorbidities in Giant Cell Arteritis: A Population-based Study

Venous thromboembolism in systemic autoimmune diseases: A narrative review with emphasis on primary systemic vasculitides

Response to: ‘Venous thromboembolic events in systemic vasculitis’ by Novikovet al

Contact Info

Product

Resources

About